Wednesday, 28 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Investor Presentation

Ambani Orgochem Investor Presentation: Key Takeaways

H1 FY27 consolidated: revenue ₹171.22 cr (+54.87%), EBITDA ₹11.32 cr (+43.00%), PAT ₹3.45 cr vs ₹0.19 cr. Strategy: capacity expansion and downstream specialty chemicals.

Highlights
Revenue growth+54.87% YoY to ₹171.22 cr consolidated
MarginsEBITDA margin ~6.6% vs ~7.2% prior year; contracted
Demand visibilityPeroxide, salicylate, acrylic demand cited; no quantified visibility
Management confidenceUpbeat MD tone; no numeric forward guidance

Growth

Revenue +54.87%, EBITDA +43.00%, PAT +1,709% off a ₹0.19 cr base. EBITDA margin fell to ~6.6% from ~7.2%.

Outlook

No quantified growth guidance. Acrylics capacity ~2,000 to ~4,500 T/month; salicylic acid ~50 to ~200 T/month; Dahej and Tarapur expansions.

Risks

EBITDA margin compression. Working capital efficiency is a stated priority. Limited global availability of certain peroxide raw materials.

Source

Investor Presentation filed with NSE, NSE: AMBANIORGO. Summary written with AI assistance from the document.

Read the document ↗

Ambani Orgochem Ltd: key numbers

Share price
₹155.05
Market cap
₹116.9 Cr
Revenue (annual)
₹240.7 Cr
Net profit (annual)
₹1.33 Cr
P/E (TTM)
87.6×Sector 34.5×
Promoter holding
52.59%
FII holding
0.00%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Ambani Orgochem Ltd

All →